Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

BACKGROUND: Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODS: ) of acquired isolates was measured with the TZM-bl assay. RESULTS: <1 μg per milliliter) per 100 person-years was 0.20 among VRC01 recipi...

Descripción completa

Guardado en:
Autores principales: Lawrence Corey, Peter B. Gilbert, Michal Juraska, David C. Montefiori, Lynn Morris, Shelly Karuna, Srilatha Edupuganti, Nyaradzo Mgodi, Allan C. deCamp, Erika Rudnicki, Yunda Huang, Pedro Gonzáles, Robinson Cabello, Catherine Orrell, Javier R. Lama, Fatima Laher, Erica Lazarus, Jorge Sánchez, Ian Frank, Juan Hinojosa, Magdalena E. Sobieszczyk, Kyle Marshall, Pamela Mukwekwerere, Joseph Makhema, Lindsey R. Baden, James I. Mullins, Carolyn Williamson, John Hural, M. Juliana McElrath, Carter Bentley, Simbarashe Takuva, Margarita M. Gomez Lorenzo, David Burns, Nicole Espy, April K. Randhawa, Nidhi Kochar, Estelle Piwowar‐Manning, Deborah Donnell, Nirupama Sista, P. Andrew, James G. Kublin, Glenda Gray, Julie E. Ledgerwood, John R. Mascola, Myron S. Cohen
Formato: Artículo
Lenguaje:inglés
Publicado: 2021
Materias:
Human immunodeficiency virus (HIV)
Antibody
Virology
Neutralizing antibody
Virus
Immunology
Medicine
Proof of Concept Study
Broadly Neutralizing Antibodies adverse effects
Broadly Neutralizing Antibodies therapeutic use
Adolescent
Adult
Americas epidemiology
Antibodies, Monoclonal adverse effects
Antibodies, Monoclonal therapeutic use
Double-Blind Method
Europe epidemiology
Female
Humans
Male
HIV Antibodies adverse effects
HIV Antibodies therapeutic use
HIV-1 drug effects
HIV Infections epidemiology
HIV Infections prevention & control
Incidence
Africa South of the Sahara epidemiology
Young Adult
Life Sciences Immunology and Microbiology Virology HIV Research and Treatment
Health Sciences Medicine Infectious Diseases HIV/AIDS drug development and treatment
Life Sciences Biochemistry, Genetics and Molecular Biology Molecular Biology Biological Research and Disease Studies
Acceso en línea:Ver en el sistema de origen
Ver en el sistema de origen
Enlace permanente (DOI o Handle)
Enlace permanente (DOI o Handle)
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Sumario:BACKGROUND: Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODS: ) of acquired isolates was measured with the TZM-bl assay. RESULTS: <1 μg per milliliter) per 100 person-years was 0.20 among VRC01 recipients and 0.86 among placebo recipients (estimated prevention efficacy, 75.4%; 95% CI, 45.5 to 88.9). The prevention efficacy against sensitive isolates was similar for each VRC01 dose and trial; VRC01 did not prevent acquisition of other HIV-1 isolates. CONCLUSIONS: VRC01 did not prevent overall HIV-1 acquisition more effectively than placebo, but analyses of VRC01-sensitive HIV-1 isolates provided proof-of-concept that bnAb prophylaxis can be effective. (Supported by the National Institute of Allergy and Infectious Diseases; HVTN 704/HPTN 085 and HVTN 703/HPTN 081 ClinicalTrials.gov numbers, NCT02716675 and NCT02568215.).

Ejemplares similares